---
title: "Alkermes plc Reports Financial Results for Q4 and Full Year 2024"
date: "2025-02-12 20:15:00"
summary: "Alkermes plc, a global biopharmaceutical company specializing in neuroscience, has released its financial results for the fourth quarter and full year ending December 31, 2024. The company also provided its financial expectations for 2025. Financial Highlights For the year 2024, Alkermes reported total revenues of $1.56 billion, a slight decrease..."
categories:
  - "TradingView"
lang:
  - "en"
translations:
  - "en"
tags:
  - "TradingView"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Alkermes plc, a global biopharmaceutical company specializing in neuroscience, has released its financial results for the fourth quarter and full year ending December 31, 2024. The company also provided its financial expectations for 2025.

**Financial Highlights**

For the year 2024, Alkermes reported total revenues of $1.56 billion, a slight decrease from $1.66 billion in 2023. The net sales of proprietary products saw an 18% year-over-year increase, reaching $1.08 billion. The company achieved a GAAP net income from continuing operations of $372 million, translating to diluted GAAP earnings per share (EPS) of $2.20.

In the fourth quarter of 2024, total revenues were $430 million, up from $377.5 million in the same period of 2023. GAAP net income from continuing operations for the quarter was $145.7 million, with a diluted EPS of $0.88.

**Business and Operational Highlights**

Alkermes' proprietary products, including VIVITROL®, ARISTADA®, and LYBALVI®, showed significant growth. VIVITROL® revenues for Q4 2024 were $134.1 million, a 31% increase compared to Q4 2023. ARISTADA® revenues grew 16% year-over-year to $96.6 million, and LYBALVI® revenues increased by 37% to $77 million.

Royalty revenues from products like XEPLION®, INVEGA TRINZA®/TREVICTA®, and INVEGA HAFYERA®/BYANNLI® amounted to $36.5 million for the fourth quarter. Manufacturing and royalty revenues from VUMERITY® were $35 million, while FAMPYRA® contributed $22.9 million.

**Strategic Initiatives and Corporate Developments**

In 2024, Alkermes repurchased $200 million of its ordinary shares and retired approximately $290 million of debt, ending the year debt-free with $825 million in cash and investments. The company also completed the sale of its manufacturing business in Ireland.

Looking ahead, Alkermes plans to advance its development pipeline, including the ongoing Phase 2 studies for ALKS 2680 in narcolepsy, with data expected in the second half of 2025. The company also aims to initiate a Phase 2 study for ALKS 2680 in idiopathic hypersomnia and advance ALKS 4510 and ALKS 7290 into Phase 1 studies.

**Management's Perspective**

Richard Pops, CEO of Alkermes, highlighted the company's transition into a highly profitable, pure-play neuroscience company. He emphasized the diversified portfolio of proprietary commercial products and the advancing development pipeline as key drivers of future growth.

Blair Jackson, COO of Alkermes, noted the company's strong financial and operational performance in 2024, including significant revenue generation, debt retirement, and progress in the neuroscience development pipeline. He reiterated the company's focus on efficiency and profitability.

**Future Outlook**

For 2025, Alkermes expects total revenues between $1.34 billion and $1.43 billion. The company projects VIVITROL® net sales to be in the range of $440 million to $460 million, ARISTADA® net sales between $335 million and $355 million, and LYBALVI® net sales between $320 million and $340 million. GAAP net income is expected to be between $175 million and $205 million, with an EBITDA range of $215 million to $245 million.

SEC Filing: [Alkermes plc. [ ALKS ] - 8-K - Feb. 12, 2025](https://www.sec.gov/Archives/edgar/data/1520262/000095017025018402/alks-20250212.htm)

[TradingView](https://www.tradingview.com/news/tradingview:f36582e679cba:0-alkermes-plc-reports-financial-results-for-q4-and-full-year-2024/)
